Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Enhancing human islet transplantation by localized release of trophic factors from PLG scaffolds.

Hlavaty KA, Gibly RF, Zhang X, Rives CB, Graham JG, Lowe WL Jr, Luo X, Shea LD.

Am J Transplant. 2014 Jul;14(7):1523-32. doi: 10.1111/ajt.12742. Epub 2014 Jun 6.

2.

Porous scaffolds support extrahepatic human islet transplantation, engraftment, and function in mice.

Gibly RF, Zhang X, Lowe WL Jr, Shea LD.

Cell Transplant. 2013;22(5):811-9.

3.

Polymer scaffolds as synthetic microenvironments for extrahepatic islet transplantation.

Blomeier H, Zhang X, Rives C, Brissova M, Hughes E, Baker M, Powers AC, Kaufman DB, Shea LD, Lowe WL Jr.

Transplantation. 2006 Aug 27;82(4):452-9.

4.

Extracellular matrix protein-coated scaffolds promote the reversal of diabetes after extrahepatic islet transplantation.

Salvay DM, Rives CB, Zhang X, Chen F, Kaufman DB, Lowe WL Jr, Shea LD.

Transplantation. 2008 May 27;85(10):1456-64. doi: 10.1097/TP.0b013e31816fc0ea.

5.

Development of an ectopic site for islet transplantation, using biodegradable scaffolds.

Dufour JM, Rajotte RV, Zimmerman M, Rezania A, Kin T, Dixon DE, Korbutt GS.

Tissue Eng. 2005 Sep-Oct;11(9-10):1323-31.

PMID:
16259588
6.

Exendin-4 does not promote Beta-cell proliferation or survival during the early post-islet transplant period in mice.

Crutchlow MF, Yu M, Bae YS, Deng S, Stoffers DA.

Transplant Proc. 2008 Jun;40(5):1650-7. doi: 10.1016/j.transproceed.2008.03.161. Erratum in: Transplant Proc. 2009 Jan-Feb;41(1):450.

7.

Permanent protection of PLG scaffold transplanted allogeneic islet grafts in diabetic mice treated with ECDI-fixed donor splenocyte infusions.

Kheradmand T, Wang S, Gibly RF, Zhang X, Holland S, Tasch J, Graham JG, Kaufman DB, Miller SD, Shea LD, Luo X.

Biomaterials. 2011 Jul;32(20):4517-24. doi: 10.1016/j.biomaterials.2011.03.009. Epub 2011 Apr 1.

8.

The effects of exendin-4 treatment on graft failure: an animal study using a novel re-vascularized minimal human islet transplant model.

Sahraoui A, Winzell MS, Gorman T, Smith DM, Skrtic S, Hoeyem M, Abadpour S, Johansson L, Korsgren O, Foss A, Scholz H.

PLoS One. 2015 Mar 20;10(3):e0121204. doi: 10.1371/journal.pone.0121204. eCollection 2015.

9.

Exendin-4 treatment improves metabolic control after rat islet transplantation to athymic mice with streptozotocin-induced diabetes.

Sharma A, Sörenby A, Wernerson A, Efendic S, Kumagai-Braesch M, Tibell A.

Diabetologia. 2006 Jun;49(6):1247-53. Epub 2006 Apr 12.

PMID:
16609877
10.

Lung-Derived Microscaffolds Facilitate Diabetes Reversal after Mouse and Human Intraperitoneal Islet Transplantation.

Abualhassan N, Sapozhnikov L, Pawlick RL, Kahana M, Pepper AR, Bruni A, Gala-Lopez B, Kin T, Mitrani E, Shapiro AM.

PLoS One. 2016 May 26;11(5):e0156053. doi: 10.1371/journal.pone.0156053. eCollection 2016.

11.

Engraftment and reversal of diabetes after intramuscular transplantation of neonatal porcine islet-like clusters.

Wolf-van Buerck L, Schuster M, Baehr A, Mayr T, Guethoff S, Abicht J, Reichart B, Nam-Apostolopoulos YC, Klymiuk N, Wolf E, Seissler J.

Xenotransplantation. 2015 Nov-Dec;22(6):443-50. doi: 10.1111/xen.12201. Epub 2015 Oct 21.

PMID:
26490671
12.

Harnessing the Foreign Body Reaction in Marginal Mass Device-less Subcutaneous Islet Transplantation in Mice.

Pepper AR, Pawlick R, Bruni A, Gala-Lopez B, Wink J, Rafiei Y, Bral M, Abualhassan N, Shapiro AM.

Transplantation. 2016 Jul;100(7):1474-9. doi: 10.1097/TP.0000000000001162.

PMID:
27136258
13.

A preconditioning regimen with a PKCɛ activator improves islet graft function in a mouse transplant model.

Hamilton D, Rugg C, Davis N, Kvezereli M, Tafti BA, Busque S, Fontaine M.

Cell Transplant. 2014;23(7):913-9. doi: 10.3727/096368913X665567. Epub 2013 Apr 2.

PMID:
23562311
14.

Extrahepatic islet transplantation with microporous polymer scaffolds in syngeneic mouse and allogeneic porcine models.

Gibly RF, Zhang X, Graham ML, Hering BJ, Kaufman DB, Lowe WL Jr, Shea LD.

Biomaterials. 2011 Dec;32(36):9677-84. doi: 10.1016/j.biomaterials.2011.08.084. Epub 2011 Sep 28.

15.

Fibroblast populated collagen matrix promotes islet survival and reduces the number of islets required for diabetes reversal.

Jalili RB, Moeen Rezakhanlou A, Hosseini-Tabatabaei A, Ao Z, Warnock GL, Ghahary A.

J Cell Physiol. 2011 Jul;226(7):1813-9. doi: 10.1002/jcp.22515.

PMID:
21506112
16.

Engraftment Site and Effectiveness of the Pan-Caspase Inhibitor F573 to Improve Engraftment in Mouse and Human Islet Transplantation in Mice.

Pepper AR, Bruni A, Pawlick R, Wink J, Rafiei Y, Gala-Lopez B, Bral M, Abualhassan N, Kin T, Shapiro AMJ.

Transplantation. 2017 Oct;101(10):2321-2329. doi: 10.1097/TP.0000000000001638.

PMID:
28072753
17.

Long-term allogeneic islet graft survival in prevascularized subcutaneous sites without immunosuppressive treatment.

Luan NM, Iwata H.

Am J Transplant. 2014 Jul;14(7):1533-42. doi: 10.1111/ajt.12739. Epub 2014 Jun 6.

18.

In vivo treatment with glucagon-like peptide 1 promotes the graft function of fetal islet-like cell clusters in transplanted mice.

Suen PM, Li K, Chan JC, Leung PS.

Int J Biochem Cell Biol. 2006;38(5-6):951-60. Epub 2005 Sep 7.

PMID:
16172015
19.

Encapsulated piscine (tilapia) islets for diabetes therapy: studies in diabetic NOD and NOD-SCID mice.

Safley SA, Cui H, Cauffiel SM, Xu BY, Wright JR Jr, Weber CJ.

Xenotransplantation. 2014 Mar-Apr;21(2):127-39. doi: 10.1111/xen.12086. Epub 2014 Mar 17.

PMID:
24635017
20.

PLG scaffold delivered antigen-specific regulatory T cells induce systemic tolerance in autoimmune diabetes.

Graham JG, Zhang X, Goodman A, Pothoven K, Houlihan J, Wang S, Gower RM, Luo X, Shea LD.

Tissue Eng Part A. 2013 Jun;19(11-12):1465-75. doi: 10.1089/ten.TEA.2012.0643. Epub 2013 Apr 3.

Supplemental Content

Support Center